FIELD: medicine.
SUBSTANCE: proprotein convertase subtilisin/kexin 9 (PCSK9) is administered to a subject in need thereof, wherein the PCSK9 inhibitor is an antibody or an antigen-binding fragment thereof. Also, PCSK9 application is proposed for manufacture of a medicament for sepsis or septic shockr treatment. A pharmaceutical composition and a commercial package containing the PCSK9 inhibitor.
EFFECT: possibility of treatment of a patient with sepsis or septic shock at doses suitable for intensive care.
21 cl, 5 dwg, 7 tbl
Title | Year | Author | Number |
---|---|---|---|
PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
PCSK9 VACCINES | 2015 |
|
RU2698971C2 |
METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
METHOD FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2010 |
|
RU2600876C2 |
COMPOSITION FOR MODULATION OF CELL ADHESION MOLECULE EXPRESSION | 2007 |
|
RU2503463C2 |
ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
METHOD FOR PREDICTING THE RISK OF DEVELOPING CORONARY HEART DISEASE BASED ON GENETIC TESTING DATA | 2021 |
|
RU2762958C1 |
ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING | 2011 |
|
RU2570729C2 |
METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
Authors
Dates
2017-11-28—Published
2013-05-17—Filed